Adalvo announces the Day 1 launch of Ticagrelor across key European markets, marking a major milestone in the company’s global growth strategy and solidifying its role as a supply chain leader in high-value products.
The launch follows the expiry of relevant patent protections, positioning Adalvo as one of the first to bring Ticagrelor to market across Europe. This execution reflects the company’s ability to deliver on time, at scale, and with full regulatory alignment across some of the most competitive and highly regulated healthcare systems in the world.
Ticagrelor, based on the reference brand Brilique, is indicated for the prevention of serious cardiovascular events in adults at high risk due to acute coronary syndromes or a history of heart attack. According to IQVIA, the product reached global sales of over $2 billion in 2024, highlighting its critical role in modern cardiovascular care.
Adalvo’s Ticagrelor launch is backed by a robust commercial and operational infrastructure, built to support large-scale deployment from Day 1. This achievement is not limited to Europe, with additional launches planned across multiple regions.
"This is a clear demonstration of our ability to lead on both regulatory execution and supply reliability," said Anil Okay, CEO of Adalvo. "Bringing Ticagrelor to market on Day 1 across major territories reflects our focus, our scale, and our commitment to delivering high-impact products when and where they matter most."
Adalvo continues to invest in global market readiness, offering partners around the world a differentiated portfolio backed by delivery precision, operational scale, and strategic foresight.
Get In Touch Today!